These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 17558415)

  • 1. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.
    Darrah PA; Patel DT; De Luca PM; Lindsay RW; Davey DF; Flynn BJ; Hoff ST; Andersen P; Reed SG; Morris SL; Roederer M; Seder RA
    Nat Med; 2007 Jul; 13(7):843-50. PubMed ID: 17558415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform.
    Darrah PA; Hegde ST; Patel DT; Lindsay RW; Chen L; Roederer M; Seder RA
    J Exp Med; 2010 Jul; 207(7):1421-33. PubMed ID: 20530206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.
    Lange UG; Mastroeni P; Blackwell JM; Stober CB
    Infect Immun; 2004 Aug; 72(8):4924-8. PubMed ID: 15271962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.
    Shimizu Y; Takagi H; Nakayama T; Yamakami K; Tadakuma T; Yokoyama N; Kojima N
    Parasite Immunol; 2007 May; 29(5):229-39. PubMed ID: 17430546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.
    Handman E; Symons FM; Baldwin TM; Curtis JM; Scheerlinck JP
    Infect Immun; 1995 Nov; 63(11):4261-7. PubMed ID: 7591056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice.
    Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Rafati S
    Parasite Immunol; 2011 Jun; 33(6):335-48. PubMed ID: 21410716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
    Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
    Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
    Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
    Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major.
    Kemp M; Handman E; Kemp K; Ismail A; Mustafa MD; Kordofani AY; Bendtzen K; Kharazmi A; Theander TG
    FEMS Immunol Med Microbiol; 1998 Mar; 20(3):209-18. PubMed ID: 9566492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
    Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
    J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis.
    Moll H; Berberich C
    Immunobiology; 2001 Dec; 204(5):659-66. PubMed ID: 11846231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
    Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
    Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites.
    Zaph C; Uzonna J; Beverley SM; Scott P
    Nat Med; 2004 Oct; 10(10):1104-10. PubMed ID: 15448686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.
    Sjölander A; Baldwin TM; Curtis JM; Bengtsson KL; Handman E
    Vaccine; 1998 Dec; 16(20):2077-84. PubMed ID: 9796067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.